Emergent BioSolutions Announces Initiation of Phase 3 Cinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19 Patients

Emergent BioSolutions | October 09, 2020

NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19. Emergent is planning additional clinical trials to evaluate COVID-HIG for potential use in other patient populations or individuals at high risk of exposure. Emergent BioSolutions, Inc. Inc. (NYSE:EBS) today announced the initiation of the Phase 3 clinical trial that will evaluate plasma-derived therapy COVID-HIG as a potential treatment for hospitalized patients with coronavirus disease (COVID-19). The INSIGHT-013 clinical study called “Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC),” is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study will evaluate the safety, tolerability, and efficacy of hyperimmune globulin products derived from plasma of individuals who have recovered from COVID-19 and have developed neutralizing antibodies to SARS-CoV-2, the virus that causes COVID-19. The randomized controlled clinical trial assigns participants to receive infusions of either a placebo or one of four hyperimmune globulin products, which includes Emergent’s COVID-HIG, with a background therapy of remdesivir in all groups.

Spotlight

B-roll of Axim Biotechnologies Inc. products and product development. This video provide information of Axim biotechnology product.

Spotlight

B-roll of Axim Biotechnologies Inc. products and product development. This video provide information of Axim biotechnology product.

Related News

Obsidian Therapeutics Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy Candidate

Obsidian Therapeutics | September 16, 2020

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the immunomodulatory factor CD40L. This announcement marks the first opt-in decision by Bristol Myers Squibb since the companies announced their collaboration to develop novel cell therapies in January 2019. Under the terms of the agreement, Obsidian is eligible to receive potential future milestone and royalty payments. "We are very interested in exploring innovative approaches to developing engineered cell therapies, including the cytoDRiVE™ platform," said Rupert Vessey, D. Phil., Executive Vice President, Research and Early Development, Bristol Myers Squibb.

Read More

CELL AND GENE THERAPY

Amyris Partners with Inscripta to Enhance Development of Sustainable Ingredients Using the Onyx™ Genome Engineering Platform

Amyris | October 06, 2021

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that Amyris has licensed the Onyx genome engineering platform from Inscripta, a leading gene editing technology company. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality. Amyris' product development and formulation team uses a proprietary Lab-to-Market™ operating system to develop and scale a growing portfolio of sustainable ingredients. The Onyx platform automates benchtop biofoundry activity and will bring greater genetic diversity and value to Amyris' ingredient development pipeline, complementing Amyris' existing Lab-to-Market operating system with the goal of improving efficiency and reducing timelines for the development of future molecules. To date, Amyris has successfully commercialized 13 sustainable ingredients, which are formulated in over 20,000 products and used by over 300 million consumers, demonstrating the growing demand for sustainable products with clean and effective ingredients. Automated, high-throughput gene editing is revolutionizing the writing of genomes the way next-generation sequencing transformed the reading of genomes. Inscripta is the first company to deliver an integrated and intuitive benchtop platform that will expand access to scalable, robust genome engineering and help scientists develop solutions to some of today's most pressing challenges. "Amyris has shown the world how new products can be made more sustainable through biology. Their team has high proficiency in utilizing cutting-edge technology, and we are excited they will be pioneering the use of our platform," said Sri Kosaraju, President and CEO of Inscripta. "We have great regard for Amyris' mission, and we are committed to seeing the Onyx platform become a substantial contributor to new clean chemistry products in the future." "The Onyx platform offers significant potential for generating greater genetic diversity in our projects, which we expect to lead to more efficient product innovation," said Sunil Chandran, Senior Vice President of Research and Development at Amyris. "Inscripta's platform seamlessly integrates with our own and opens up new experimentation avenues for our scientists to continue bringing unique bio-based products to customers. We pride ourselves on continuous innovation and expect Onyx to help us expand our pipeline, while achieving lower costs and reducing time to market." For more information about Amyris visit amyris.com and to learn about Onyx, visit www.inscripta.com/products. About Inscripta Inscripta is a life science technology company enabling scientists to solve some of today's most pressing challenges with the first benchtop system for genome editing. The company's automated Onyx platform, consisting of an instrument, consumables, assays, and software, makes CRISPR-based genome engineering accessible to any research lab. Inscripta supports its customers around the world from facilities in Boulder, Colorado; San Diego and Pleasanton, California; and Copenhagen, Denmark. To learn more, visit Inscripta.com and follow @InscriptaInc. About Amyris Amyris (Nasdaq: AMRS) is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris is proud to own and operate a family of consumer brands - all built around its No Compromise® promise of clean ingredients: Biossanceâ clean beauty skincare, Pipetteâ clean baby skincare, Purecane™, a zero-calorie sweetener naturally derived from sugarcane, Terasanaâ clean skincare treatment, Costa Brazil luxury skincare, OLIKA hygiene and wellness, Rose Inc.™ clean color cosmetics and JVN™ clean haircare.

Read More

Sartorius Stedim Biotech Closes Acquisition of Slovenian Purification Specialist BIA Separations

Sartorius | November 03, 2020

Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of the Slovenian purification specialist BIA Separations. The transaction was completed on November 2, 2020, after receiving the required approvals. "BIA's portfolio is highly complementary to Sartorius Stedim Biotech. We are thus creating an excellent offering for the manufacturing of gene therapies and other advanced therapies, and are pleased to welcome 120 new employees," said Dr. Joachim Kreuzburg, Chairman of the Board and CEO of Sartorius Stedim Biotech. The total purchase price of the transaction is 360 million euros of which 240 million euros were paid in cash and 120 million euros in SSB shares. Both parties have further agreed on three tranches of earn-out payments based on performance over the next five financial years. SSB has been preparing to integrate BIA Separations so this can now be initiated despite the special conditions prevailing during the pandemic. BIA Separations develops and manufactures market-leading products for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are used in cell and gene therapies and other advanced therapies. BIA's technology for manufacturing-scale purification is already used in production of the first commercialized advanced therapeutics, and the company also has a strong presence with such novel drug candidates in the clinical pipeline. Expecting continued very strong double-digit sales growth over the next few years, BIA is forecasted to earn sales revenue of approx. 25 million euros in 2020 at profit margins that will be accretive to the underlying EBITDA margin of the Sartorius Stedim Biotech Group. The transaction is not expected to have any material impact on Sartorius Stedim Biotech's 2020 results.

Read More